Pre-gestational diabetes, type 1 diabetes (T1DM) and type 2 diabetes (T2DM) are associated with adverse outcomes: miscarriage, stillbirth, macrosomia and increased rates of emergency cesarean sections (EMCS). We reviewed 175 women with pre-gestational diabetes who attended the National Maternity Hospital in Dublin, Ireland between 2015 to 2017. Fifty women (28.6%) had T2DM and 125 women (71.4%) had T1DM. The mean age for T1DM group was (34 ± 4.7years) and T2DM (35.5 ± 3.8 years). Most of our patients were of European descent (85%) others were mostly of Asian and North African origin (15%). Mean duration of diabetes was 5.4 years in T2DM and 15.7 years in T1DM. Structured pre-pregnancy planning attended by 38.3% of our patients. Pre-pregnancy folic acid was used by 45.7% of patients for at least one month prior to booking. Forty women (29%) of T1DM were on Continuous Subcutaneous Insulin Infusion (CSII). Patients with T2DM were treated with Metformin (20%) only, Metformin and multiple dose insulin (MDI) injection combined (44%), MDI (28%) and diet control alone (2%). Mean BMI for T2DM was 32.6 ± 8.1 kg/m2 at booking and for T1DM 26.2 ± 4.5 kg/m2. Diabetic Retinopathy was more frequent in T1DM. The HBA1C in CSII group was 53.5 mmol/mol in the first trimester and improved to 42.9 mmol/mol in the third. T1DM group on MDI had HBA1C of 56.9 mmo/mol at booking and 44.7 mmol/mol in the third trimester. The mean HBA1C in T2DM at booking was 44.5 mmol/mol and 37.5 mmol/mol in the third trimester. Cesarean section (CS) was common in T1DM 48% with mostly EMCS 32%. In T2DM rate of CS was 38%. The most neonatal ICU (NICU) admission was due to hypoglycemia; in the T1DM group was 16.5% and 10% in T2DM group. Total neonatal birth weights above 4.0 Kg in our cohort was 21.7%. Our cohort with pre-gestational diabetes were overweight, older with long standing diabetes. Initial inadequate diabetes control in T1DM was better in patients with CSII with a significant improvement during pregnancy in all patients. With appropriate multidisciplinary treatment we minimized adverse outcomes.

Disclosure

D.S.A. Ali: None. M. Hatunic: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.